Novartis: positive results for COPD bronchodilator.
(CercleFinance.com) - Novartis' Ultibro Breezhaler significantly improved chronic obstructive pulmonary disease (COPD) patients' lung function after direct switch from Seretide, the Swiss drugmaker said on Monday.
A study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide to Ultibro Breezhaler met its primary endpoint, demonstrating that switching resulted in a significantly improved lung function, Novartis said.
The study's results were presented at the Asian Pacific Society of Respirology (APSR) Congress, which is currently being held in Sydney, Australia.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide to Ultibro Breezhaler met its primary endpoint, demonstrating that switching resulted in a significantly improved lung function, Novartis said.
The study's results were presented at the Asian Pacific Society of Respirology (APSR) Congress, which is currently being held in Sydney, Australia.
Copyright (c) 2017 CercleFinance.com. All rights reserved.